Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploration of the Efficacy and Safety of Orelabrutinib Combined With Rituximab and Methotrexate (ORM Regimen) in the First-line Treatment of Primary Central Nervous System Lymphoma

Next Previous
Trial Profile

Exploration of the Efficacy and Safety of Orelabrutinib Combined With Rituximab and Methotrexate (ORM Regimen) in the First-line Treatment of Primary Central Nervous System Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Methotrexate (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary) ; Thiotepa (Primary) ; Busulfan; Cytarabine
  • Indications CNS cancer; Lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jun 2025 According to an InnoCare Pharma media release the data from this study has been presented at the European Hematology Association (EHA) 2025 Congress.
  • 13 Jun 2025 Results presented in an InnoCare Pharma media release.
  • 09 Dec 2024 According to an InnoCare Pharma media release, preliminary data from this study were were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top